Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study
Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study. Hepatology 2017, 66: 1090-1101. PMID: 28504842, PMCID: PMC5756478, DOI: 10.1002/hep.29258.Peer-Reviewed Original ResearchConceptsSustained virologic responseOmbitasvir/paritaprevir/ritonavirParitaprevir/ritonavirTransplant recipientsLiver transplantKidney transplantAntiviral therapyLarge prospective observational cohort studyChronic hepatitis C virusLiver-kidney transplant recipientsProspective observational cohort studySolid organ transplant recipientsHepatitis C virus (HCV) treatmentBaseline total bilirubinHCV-TARGET studyPrior antiviral therapyAbsence of cirrhosisKidney transplant recipientsLiver transplant recipientsObservational cohort studyOrgan transplant recipientsC virus treatmentGlomerular filtration rateCessation of treatmentSOF/ledipasvir